Cardiovascular Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease

Cardiovascular disease (CVD) poses a major risk in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and is often left untreated. It is highly important that physicians screen patients with MASLD for CVD and initiate treatment accordingly. The cornerstone of MASLD treatment is lifestyle intervention focusing on weight loss with or without anti-hyperlipidemic drugs.